Quick Answer
Biohaven Ltd. reported Cash And Cash Equivalents At Carrying Value of $229.96 million for the year ending 2025.
- Biohaven Ltd. showed an increase of +132.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Biohaven Ltd.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $361.70 million | Q1 2022: $40.26 million | Q2 2022: $23.21 million | Q3 2022: $50.67 million | Q1 2023: $125.03 million | Q2 2023: $147.61 million | Q3 2023: $111.70 million | Q1 2024: $182.71 million | Q2 2024: $239.15 million | Q3 2024: $84.39 million | Q1 2025: $98.42 million | Q2 2025: $165.80 million | Q3 2025: $184.85 million.
- Over the full 6 years of available data (2020 to 2025), Biohaven Ltd.'s Cash And Cash Equivalents At Carrying Value has grown by 178.7%.
- Historical annual values: Fiscal year 2025: $229.96 million | Fiscal year 2024: $99.13 million | Fiscal year 2023: $248.40 million | Fiscal year 2022: $204.88 million | Fiscal year 2021: $76.06 million | Fiscal year 2020: $82.51 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: